Nanotechnology-Mediated Nose-to-Brain Drug Delivery for Neurodegenerative Disorders

2019 ◽  
pp. 163-175
Author(s):  
Chandrakantsing V. Pardeshi ◽  
Veena S. Belgamwar ◽  
Sanjay J. Surana
Keyword(s):  
Drug Delivery ◽  
Neurodegenerative Disorders ◽  
Brain Drug Delivery

Brain Drug Delivery: Overcoming the Blood-brain Barrier to Treat Tauopathies

2020 ◽  
Vol 26 (13) ◽  
pp. 1448-1465 ◽  
Author(s):  
Jozef Hanes ◽  
Eva Dobakova ◽  
Petra Majerova
Keyword(s):  
Drug Delivery ◽  
Blood Brain Barrier ◽  
Neurodegenerative Disorders ◽  
Brain Barrier ◽  
Neuronal Function ◽  
Brain Drug Delivery ◽  
Naturally Occurring ◽  
Blood Brain ◽  
Traditional Approaches ◽  
The Brain

Tauopathies are neurodegenerative disorders characterized by the deposition of abnormal tau protein in the brain. The application of potentially effective therapeutics for their successful treatment is hampered by the presence of a naturally occurring brain protection layer called the blood-brain barrier (BBB). BBB represents one of the biggest challenges in the development of therapeutics for central nervous system (CNS) disorders, where sufficient BBB penetration is inevitable. BBB is a heavily restricting barrier regulating the movement of molecules, ions, and cells between the blood and the CNS to secure proper neuronal function and protect the CNS from dangerous substances and processes. Yet, these natural functions possessed by BBB represent a great hurdle for brain drug delivery. This review is concentrated on summarizing the available methods and approaches for effective therapeutics’ delivery through the BBB to treat neurodegenerative disorders with a focus on tauopathies. It describes the traditional approaches but also new nanotechnology strategies emerging with advanced medical techniques. Their limitations and benefits are discussed.

scholarly journals Brain Drug Delivery Systems for Neurodegenerative Disorders

2012 ◽  
Vol 13 (12) ◽  
pp. 2388-2402 ◽  
Author(s):  
E. Garbayo ◽  
E. Ansorena ◽  
M.J. Blanco-Prieto
Keyword(s):  
Drug Delivery ◽  
Neurodegenerative Disorders ◽  
Drug Delivery Systems ◽  
Delivery Systems ◽  
Brain Drug Delivery

scholarly journals Nose-to-Brain drug delivery via nanocarriers for the management of neurodegenerative disorders: recent advances and future

2022 ◽  
Vol 01 (01) ◽  
pp. 19-34
Author(s):  
Vishesh Singh ◽  
Arun Singh Lalotra ◽  
Shelly Agrawal ◽  
Gaurav Mishra
Keyword(s):  
Drug Delivery ◽  
Neurodegenerative Disorders ◽  
Brain Drug Delivery ◽  
Recent Advances

Nose-to-Brain Drug Delivery by Nanoparticles in the Treatment of Neurological Disorders

2014 ◽  
Vol 21 (37) ◽  
pp. 4247-4256 ◽  
Author(s):  
Wei-Yi Ong ◽  
Suku-Maran Shalini ◽  
Luca Costantino
Keyword(s):  
Drug Delivery ◽  
Neurological Disorders ◽  
Brain Drug Delivery

Polymeric Nanoparticles for Brain Drug Delivery - A Review

2020 ◽  
Vol 21 (9) ◽  
pp. 649-660
Author(s):  
Subashini Raman ◽  
Syed Mahmood ◽  
Ayah R. Hilles ◽  
Md Noushad Javed ◽  
Motia Azmana ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Surface Modification ◽  
Polymeric Nanoparticles ◽  
Drug Loading ◽  
Preparation Methods ◽  
Brain Drug Delivery ◽  
Polymeric Nanoparticle ◽  
Relationship Of ◽  
The Relationship ◽  
The Brain

Background: Blood-brain barrier (BBB) plays a most hindering role in drug delivery to the brain. Recent research comes out with the nanoparticles approach, is continuously working towards improving the delivery to the brain. Currently, polymeric nanoparticle is extensively involved in many therapies for spatial and temporal targeted areas delivery. Methods: We did a non-systematic review, and the literature was searched in Google, Science Direct and PubMed. An overview is provided for the formulation of polymeric nanoparticles using different methods, effect of surface modification on the nanoparticle properties with types of polymeric nanoparticles and preparation methods. An account of different nanomedicine employed with therapeutic agent to cross the BBB alone with biodistribution of the drugs. Results: We found that various types of polymeric nanoparticle systems are available and they prosper in delivering the therapeutic amount of the drug to the targeted area. The effect of physicochemical properties on nanoformulation includes change in their size, shape, elasticity, surface charge and hydrophobicity. Surface modification of polymers or nanocarriers is also vital in the formulation of nanoparticles to enhance targeting efficiency to the brain. Conclusion: More standardized methods for the preparation of nanoparticles and to assess the relationship of surface modification on drug delivery. While the preparation and its output like drug loading, particle size, and charge, permeation is always conflicted, so it requires more attention for the acceptance of nanoparticles for brain delivery.

Brain Drug Delivery System: An Overview

2010 ◽  
Vol 5 (2) ◽  
pp. 105-110 ◽  
Author(s):  
Pushpanjali C. Ligade ◽  
Kisan R. Jadhav ◽  
Vilasrao J. Kadam
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Brain Drug Delivery

scholarly journals Current Strategies for Brain Drug Delivery

Theranostics ◽  
2018 ◽  
Vol 8 (6) ◽  
pp. 1481-1493 ◽  
Author(s):  
Xiaowei Dong
Keyword(s):  
Drug Delivery ◽  
Brain Drug Delivery

scholarly journals Blood-brain barrier opening with focused ultrasound in Parkinson’s disease dementia

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Carmen Gasca-Salas ◽  
Beatriz Fernández-Rodríguez ◽  
José A. Pineda-Pardo ◽  
Rafael Rodríguez-Rojas ◽  
Ignacio Obeso ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Neurodegenerative Disorders ◽  
Focused Ultrasound ◽  
Temporal Cortex ◽  
Clinical State ◽  
Cognitive Improvement ◽  
Bbb Opening

AbstractMR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, has been applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. MRgFUS could become a therapeutic tool for drug delivery of putative neurorestorative therapies. Treatment for Parkinson’s disease with dementia (PDD) is an important unmet need. We initiated a prospective, single-arm, non-randomized, proof-of-concept, safety and feasibility phase I clinical trial (NCT03608553), which is still in progress. The primary outcomes of the study were to demonstrate the safety, feasibility and reversibility of BBB disruption in PDD, targeting the right parieto-occipito-temporal cortex where cortical pathology is foremost in this clinical state. Changes in β-amyloid burden, brain metabolism after treatments and neuropsychological assessments, were analyzed as exploratory measurements. Five patients were recruited from October 2018 until May 2019, and received two treatment sessions separated by 2–3 weeks. The results are set out in a descriptive manner. Overall, this procedure was feasible and reversible with no serious clinical or radiological side effects. We report BBB opening in the parieto-occipito-temporal junction in 8/10 treatments in 5 patients as demonstrated by gadolinium enhancement. In all cases the procedures were uneventful and no side effects were encountered associated with BBB opening. From pre- to post-treatment, mild cognitive improvement was observed, and no major changes were detected in amyloid or fluorodeoxyglucose PET. MRgFUS-BBB opening in PDD is thus safe, reversible, and can be performed repeatedly. This study provides encouragement for the concept of BBB opening for drug delivery to treat dementia in PD and other neurodegenerative disorders.

scholarly journals Biodegradable polyanhydride-based nanomedicines for blood to brain drug delivery

2018 ◽  
Vol 106 (11) ◽  
pp. 2881-2890 ◽  
Author(s):  
Timothy M. Brenza ◽  
Benjamin W. Schlichtmann ◽  
Biju Bhargavan ◽  
Julia E. Vela Ramirez ◽  
Rainie D. Nelson ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Brain Drug Delivery
Sign in / Sign up

Export Citation Format

Share Document